Mark Matson

935 total citations
25 papers, 577 citations indexed

About

Mark Matson is a scholar working on Oncology, Epidemiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mark Matson has authored 25 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Epidemiology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mark Matson's work include Antifungal resistance and susceptibility (2 papers), Multiple Sclerosis Research Studies (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mark Matson is often cited by papers focused on Antifungal resistance and susceptibility (2 papers), Multiple Sclerosis Research Studies (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Mark Matson collaborates with scholars based in United States, Sweden and Japan. Mark Matson's co-authors include Eric P. Cohen, Maurice G. Emery, Blaire Cooke, John P. Gibbs, Karen Smirnakis, Evan A. Stein, Scott M. Wasserman, Bing Gao, Brian P. Smith and Adam J. Shaywitz and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Mark Matson

25 papers receiving 560 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Matson United States 10 230 151 112 93 86 25 577
Poorya Amini Switzerland 7 181 0.8× 165 1.1× 59 0.5× 44 0.5× 62 0.7× 9 671
Alison Taylor United Kingdom 13 381 1.7× 124 0.8× 36 0.3× 69 0.7× 38 0.4× 15 577
Tom Nguyen United States 18 143 0.6× 243 1.6× 290 2.6× 119 1.3× 36 0.4× 35 875
Rangaswamy Govindarajan United States 12 225 1.0× 427 2.8× 130 1.2× 58 0.6× 18 0.2× 39 973
Yoshihiro Noji Japan 10 131 0.6× 68 0.5× 47 0.4× 28 0.3× 18 0.2× 20 389
Bernie Fitzharris United Kingdom 10 129 0.6× 111 0.7× 72 0.6× 55 0.6× 11 0.1× 11 474
Myla Lai-Goldman United States 10 69 0.3× 146 1.0× 94 0.8× 31 0.3× 10 0.1× 14 473
Biao Nie China 11 202 0.9× 243 1.6× 64 0.6× 262 2.8× 9 0.1× 20 785
Mark H. Einstein United States 17 108 0.5× 367 2.4× 93 0.8× 172 1.8× 10 0.1× 32 1.2k

Countries citing papers authored by Mark Matson

Since Specialization
Citations

This map shows the geographic impact of Mark Matson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Matson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Matson more than expected).

Fields of papers citing papers by Mark Matson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Matson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Matson. The network helps show where Mark Matson may publish in the future.

Co-authorship network of co-authors of Mark Matson

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Matson. A scholar is included among the top collaborators of Mark Matson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Matson. Mark Matson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manna, Laura, et al.. (2024). First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects. Stroke. 55(12). 2795–2803. 3 indexed citations
2.
Matson, Mark, et al.. (2020). VDR in salivary gland homeostasis and cancer. The Journal of Steroid Biochemistry and Molecular Biology. 199. 105600–105600. 5 indexed citations
3.
4.
Bose, Nandita, Xiaohong Qiu, Mark Uhlik, et al.. (2019). Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers. The Journal of Immunology. 202(10). 2945–2956. 12 indexed citations
5.
6.
Duus, Elizabeth Manning, Mark Matson, & A. Bernareggi. (2018). Effects of strong cytochrome P450 (CYP)3A4 inducers/inhibitors on the pharmacokinetic (PK) profile of anamorelin in healthy volunteers.. Journal of Clinical Oncology. 36(15_suppl). e22180–e22180. 1 indexed citations
7.
Bose, Nandita, Mark Matson, Xiaohong Qiu, et al.. (2017). Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers.. Journal of Clinical Oncology. 35(7_suppl). 33–33. 1 indexed citations
8.
Hu, Xiao, Ali Seddighzadeh, Ying Zhu, et al.. (2014). Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta‐1a in subjects with normal or impaired renal function. The Journal of Clinical Pharmacology. 55(2). 179–188. 8 indexed citations
9.
Devane, John, Mary Lane Martin, & Mark Matson. (2014). A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment. Current Medical Research and Opinion. 30(6). 1179–1187. 12 indexed citations
10.
Dias, Clapton, Adam J. Shaywitz, Scott M. Wasserman, et al.. (2012). Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology. 60(19). 1888–1898. 202 indexed citations
11.
Shaywitz, Adam J., Clapton Dias, Brian P. Smith, et al.. (2012). AMG 145, a Fully Human Monoclonal Antibody Against PCSK9, Reduces LDL-C in Healthy Volunteers and Patients on Stable Doses of Statins†. Journal of clinical lipidology. 6(3). 286–287. 3 indexed citations
12.
Dias, Clapton, Adam J. Shaywitz, Brian D. Smith, et al.. (2011). Abstract 10701: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145. Circulation. 124. 8 indexed citations
13.
Reitman, Marc L., Victor Dishy, William S. Denney, et al.. (2011). Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients. The Journal of Clinical Pharmacology. 52(9). 1306–1316. 38 indexed citations
14.
Matson, Mark, et al.. (2011). Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation. Current Medical Research and Opinion. 27(12). 2271–2278. 9 indexed citations
15.
Pentikis, Helen S., Mark Matson, George Atiee, et al.. (2011). Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers. Antimicrobial Agents and Chemotherapy. 55(6). 2847–2854. 33 indexed citations
16.
Matson, Mark, et al.. (2009). A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects. Antiviral Research. 82(2). A49–A49. 2 indexed citations
17.
Matson, Mark, et al.. (2009). A Study of the Safety and Pharmacokinetics of Single and Multiple Doses of FV-100 in Subjects 65 Years and Over. Antiviral Research. 82(2). A49–A49. 1 indexed citations
18.
Matson, Mark & Eric P. Cohen. (1990). Acquired Cystic Kidney Disease. Medicine. 69(4). 217–226. 155 indexed citations
19.
Jacobson, Stefan H., David S. Fryd, Lars‐Eric Lins, et al.. (1988). Transplantation, hemodialysis, and continuous ambulatory peritoneal dialysis for end-stage renal disease in diabetic patients. Journal of Diabetic Complications. 2(3). 150–157. 6 indexed citations
20.
Matson, Mark. (1988). Long-term Follow-up of 369 Diabetic Patients Undergoing Dialysis. Archives of Internal Medicine. 148(3). 600–600. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Poorya Amini Breakdown of academic impact, for papers by Alison Taylor Breakdown of academic impact, for papers by Tom Nguyen Breakdown of academic impact, for papers by Rangaswamy Govindarajan Breakdown of academic impact, for papers by Yoshihiro Noji Breakdown of academic impact, for papers by Bernie Fitzharris Breakdown of academic impact, for papers by Myla Lai-Goldman Breakdown of academic impact, for papers by Biao Nie Breakdown of academic impact, for papers by Mark H. Einstein
Rankless by CCL
2026